Clinical trials: Myelodysplastic Syndrome
Myelodysplastic Syndromes
Sterile Inflammation and Molecular Aberrations in MDS
The objective of this study is the description of the possible association between genetic mutation/aberration profiles, inflammatory tonus and clinical phenotype based on PROMs and HRQoL.
- Trial name
- InflamGen (NCT04313231)
- Testing
- Next Generation Sequencing, Tumorimmunological examinations - multiplex assays/quantitative polymerase chain reaction, flow cytometry
- Where
- Austria
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- Medical University Innsbruck
Acute Myelogenous Leukemia, Multiple Myeloma
Collect and Assess Tissue Samples From Subjects With Hematologic Malignancy
This is a prospective, multicenter observational study to collect clinically annotated biospecimens in order to assess the correlation between ex vivo data generated by the Notable assay platform and clinical outcome.
- Conditions
- Acute Myelogenous Leukemia, Multiple Myeloma, Myelodysplastic Syndromes, Lymphoma
- Trial name
- (ANSWer) (NCT04014764)
- Testing
- This is a non-interventional study
- Where
- 20 sites in United States, Greece and 1 more
- Volunteers
- 119 people
- Sponsor
- Notable Labs
Myelodysplastic Syndromes, Acute Leukemia
CIK-Cells in Relapsing Patients With Acute Leukemia or Myelodysplastic Syndromes After SCT.
Multi-site, non-randomized Phase I/II study involving children and adults.
- Trial name
- NCT02752243
- Testing
- CIK-Cells
- Where
- 5 sites in Germany
- Volunteers
- 32 people
- Sponsor
- Peter Bader
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
Safety and Efficiency of γδ T Cell Against Hematological Malignancies After Allo-HSCT
This study investigates the infusion safety and potential curative properties of ex-vivo expanded γδ T cells obtained from the same donor for patients who have hematological malignancies and have accepted allogeneic hematopoietic…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Lymphoma
- Trial name
- NCT04764513
- Testing
- Ex-vivo expanded γδ T cell infusion
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Chinese PLA General Hospital
Myelodysplastic Syndromes, Secondary Acute Myeloid Leukemia (AML)
A Dose Confirmation Study of Oral Clofarabine for Adult Patients Previously Treated for Myelodysplastic Syndromes (MDS)
There was no well accepted standard of care for participants who failed or were intolerant to any of the currently approved therapies for myelodysplastic syndromes (MDS).
- Trial name
- NCT00531232
- Testing
- Clofarabine
- Where
- 6 sites in United States
- Volunteers
- 38 people
- Sponsor
- Genzyme, a Sanofi Company
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Study With Intravenous Busulfan And Fludarabine Myeloablative Conditioning Regimen For HLA Identical Sibling Donor HSCT
Analyze the results of conditioning with once-daily dose intravenous busulfan and fludarabine in patients undergoing HLA identical sibling Allogeneic HSCT for myeloid malignancies.
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myeloproliferative Disorders, Chronic Myeloid Leukemia
- Trial name
- BUFLU (NCT01683123)
- Volunteers
- 143 people
- Sponsor
- Grupo Espanol de trasplantes hematopoyeticos y terapia celular
Chronic Myeloid Leukemia, Myelodysplastic Syndrome
Expanded Use of G-CSF Mobilized Donor CD34+ Selected Cells for Allogeneic Transplantation
Allogeneic hematopoietic stem cell transplantation (HSCT) is an established form of treatment for hematological abnormalities. Poor graft function, occurs when there poor donor engraftment.
- Conditions
- Chronic Myeloid Leukemia, Myelodysplastic Syndrome, Acute Myeloid Leukemia
- Trial name
- NCT02258490
- Testing
- G-CSF mobilized CD34+ selected cells for transplantation
- Where
- United States
- Sponsor
- Emory University
Acute Myeloid Leukaemia; Myelodysplastic Syndromes;Chronic Myelomonocytic Leukemia
Azacytidine + HAG Regimen vs. Azacytidine for Elderly Patients With Newly Diagnosed Myeloid Malignancy
The primary objective is to explore the efficacy and safety of azacytidine and HAG regimen versus azacytidine for elderly patients with Newly Diagnosed MDS/AML/CMML in China.
- Trial name
- NCT03873311
- Testing
- Azacytidine, HAG Regimen, Azacytidine
- Where
- China
- Volunteers
- 114 people
- Sponsor
- Shenzhen Second People's Hospital
Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDS
Patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) will receive lymphodepleting chemotherapy (Flu/Cy) and two infusions of cytokine-induced memory-like NK cells at the previously…
- Conditions
- Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT04893915
- Testing
- Cytokine-induced memory-like NK cells, Fludarabine, Cyclophosphamide
- Sponsor
- Washington University School of Medicine
Acute Myeloid Leukemia, Myelodysplastic Syndrome
Study of Lenalidomide in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome
The purpose of this study is to determine whether lenalidomide can stop the growth of leukemia stem cells and can be used to prevent the return of leukemia cells after a transplant.
- Trial name
- NCT01433965
- Testing
- Lenalidomide
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- University of California, Davis
Myelodysplastic Syndromes
Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic Syndromes
The purpose of this study is to see if selinexor will improve the blood counts and bone marrow function in people with your type of MDS.
- Trial name
- NCT02228525
- Testing
- selinexor (KPT-330)
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Acute Myeloid Leukemia, Chronic Myeloid Leukemia
IMRT-TMI With Fludarabine as Myeloablative Conditioning for Allogeneic HSCT
This is a phase I/II clinical trial on the use of total marrow irradiation (TMI) given concurrently with fludarabine, a chemotherapy drug commonly used to treat leukemia, as a myeloablative therapy for patients undergoing…
- Conditions
- Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT03696537
- Testing
- Fludarabine, Total Marrow Irradiation (TMI)
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Naoyuki G. Saito, M.D., Ph.D.
Myelodysplastic Syndromes
A Safety and Efficacy Study of Pracinostat and Azacitidine in Patients With High Risk Myelodysplastic Syndromes
This is a Phase 2, two-stage study of the safety and efficacy of pracinostat in combination with azacitidine in patients with IPSS-R high and very high risk myelodysplastic syndrome (MDS) who are previously untreated with…
- Trial name
- NCT03151304
- Testing
- Pracinostat, Azacitidine
- Where
- 25 sites in United States
- Volunteers
- 64 people
- Sponsor
- Helsinn Healthcare SA
Haematological Malignancy, Acute Leukemia
A Study to Assess a Physical Activity Program in Children, Adolescents and Young Adults Requiring Hematopoietic Stem Cell Allografts
To date, allogeneic haematopoietic stem cell transplantation (aHSCT) is the only curative treatment for many paediatric and young adult haematological pathologies (acute leukaemia, myelodysplastic syndromes, haemoglobinopathies…
- Conditions
- Haematological Malignancy, Acute Leukemia, Myelodysplastic Syndromes, Hemoglobinopathy in Children
- Trial name
- EVAADE (NCT04331483)
- Testing
- Physical activity program
- Where
- France
- Sponsor
- Centre Leon Berard
Myelodysplastic Syndrome, Allogeneic Hematopoietic Stem Cell Transplantation
G-CSF+Decitabine+BUCY vs BUCY Conditioning Regimen for RAEB-1, REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) appears to be an efficient tool to cure refractory anemia with excess blasts-1 (RAEB-1), refractory anemia with excess blasts-2 (RAEB-2) and acute myeloid leukemia…
- Conditions
- Myelodysplastic Syndrome, Allogeneic Hematopoietic Stem Cell Transplantation, Conditioning
- Trial name
- NCT02744742
- Testing
- Decitabine, Busulfan (BU), Cyclophosphamide (CY)
- Where
- China
- Volunteers
- 202 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Myelodysplastic Syndrome RAEB-I or RAEB-II, Refractory Acute Myeloid Leukemia
GM-CSF Vaccinations After Allogeneic Blood Stem Cell Transplantation in Patients With Advanced Myeloid Malignancies
The purpose of this study is to investigate whether the addition of a vaccine after participants reduced intensity transplant will be safe and beneficial.
- Conditions
- Myelodysplastic Syndrome RAEB-I or RAEB-II, Refractory Acute Myeloid Leukemia, Refractory CML Myeloid Blast Crisis
- Trial name
- NCT00426205
- Testing
- GM-CSF secreting leukemia vaccine
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Dana-Farber Cancer Institute
Childhood Acute Basophilic Leukemia, Childhood Acute Eosinophilic Leukemia
Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes
This phase III trial is studying how well combination chemotherapy works in treating young patients with Down syndrome and acute myeloid leukemia or myelodysplastic syndromes.
- Conditions
- Childhood Acute Basophilic Leukemia, Childhood Acute Eosinophilic Leukemia, Childhood Acute Erythroleukemia (M6), Childhood Acute Megakaryocytic Leukemia (M7)
- Trial name
- NCT00369317
- Testing
- asparaginase, daunorubicin hydrochloride, cytarabine
- Where
- 97 sites in United States, Australia and 2 more
- Volunteers
- 205 people
- Sponsor
- Children's Oncology Group
Myelodysplastic Syndromes, Thrombocytopenia
Eltrombopag for the Treatment of Thrombocytopenia Due to Low- and Intermediate Risk Myelodysplastic Syndromes
Myelodysplastic syndromes (MDS) prevail in older age and are characterized by ineffective erythropoiesis and peripheral cytopenias. Supportive therapy is the main therapeutic option for most patients.
- Trial name
- NCT02912208
- Testing
- Eltrombopag/Revolade
- Where
- 64 sites in France, Germany and 2 more
- Volunteers
- 174 people
- Sponsor
- Associazione Qol-one
Myelodysplastic Syndrome, Acute Myeloid Leukemia
Phase 1b/2 Safety and Efficacy of APR-246 w/Azacitidine for tx of TP53 Mutant Myeloid Neoplasms
The main purpose of this study is to determine the safe and recommended dose of APR-246 in combination with azacitidine as well as to see if this combination of therapy improves overall survival.
- Conditions
- Myelodysplastic Syndrome, Acute Myeloid Leukemia, Myeloproliferative Neoplasm, Chronic Myelomonocytic Leukemia
- Trial name
- NCT03072043
- Testing
- APR-246, Azacitidine
- Where
- 6 sites in United States
- Volunteers
- 55 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Myelodysplastic Syndromes
Mean Platelet Volume and Its Relation to Risk Stratification of Myelodysplastic Syndromes
The myelodysplastic syndromes (MDS) are a group of myeloid neoplasms characterized by abnormal differentiation and maturation of myeloid cells, reduced bone marrow (BM) function, and a genetic instability with enhanced risk to…
- Trial name
- NCT05204953
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- Assiut University